The role of CXCL12 in the bone marrow (BM) homing and growth of B-cell progenitor acute lymphoblastic leukemia (ALL) has been established. However, the effect of modulating CXCL12/CXCR4 interactions on the retention of ALL cells within the supportive BM microenvironment and the expansion and dissemination of ALL cells in vivo has not been examined. We used mouse models of human childhood and murine leukemia and specific peptide and small molecule CXCR4 antagonists to examine the importance of CXCL12/CXCR4 in the development of leukemia in vivo. CXCR4 antagonists mobilized ALL cells into the peripheral blood (PB). Extended administration of CXCR4 antagonists to mice with leukemia resulted in a reduction in the number of leukemic cells in the PB and spleens of animals compared to control treated animals in three of the five cases tested. There was also a marked reduction in the dissemination of ALL cells to extramedullary sites including liver and kidney in all cases where this occurred. Considering the inhibitory effect of stromal layers on the activity of chemotherapeutic agents and the interactive effect of CXCL12 antagonists with chemotherapeutic agents in vitro, this raises the possibility of using these agents to potentiate the effects of current chemotherapy regimens.
Introduction
Despite the dramatic improvements in outcome, resulting from the refinement of multiagent chemotherapeutic and radiotherapy regimens, acute lymphoblastic leukemia (ALL) remains a major cause of death in children. 1 The majority of ALL cases arise from B-cell progenitors (precursor B-ALL) in the bone marrow (BM) and although approximately 70% of children are cured, the treatment options for those who relapse are limited and mortality in this group is high. More intensive treatment regimens are often limited by their toxicity, consequences of which have become a significant issue in long-term survivors. 2 Stromal derived factor-1a or CXCL12, is a potent chemokine acting on hematopoietic cells and its receptor, CXCR4, is widely expressed, on normal hematopoietic cells, including multipotent stem cells. 3 Within the BM microenvironment, the highest levels of CXCL12 are detected on osteoblasts located at the endosteum and BM endothelial cells with CXCL12 and CXCR4 playing a role in both homing of normal human progenitors to the BM and the efficient multilineage engraftment of human progenitors in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. 4, 5 More recently, CXCL12 has been implicated in the retention of hematopoietic progenitors within the BM, with the disruption of CXCL12/CXCR4 interactions resulting in the rapid mobilization of progenitors into the peripheral blood (PB). 6, 7 CXCL12 also plays a significant role in the proliferation and survival of normal human CD34 þ cells, often in synergy with other growth factors. 8, 9 The chemotactic function of CXCL12 has also been implicated in the growth and metastasis of solid tumors. [10] [11] [12] The importance of CXCL12 for B lymphopoiesis is apparent from the complete lack of B lineage cells in CXCL12-and CXCR4-knockout mice. [13] [14] [15] We have previously demonstrated that CXCR4 is highly expressed on all cases of precursor B ALL and that these cells are highly chemotactic toward CXCL12. 16 CXCL12 plays a significant role in the homing of precursor B ALL to the BM and their subsequent engraftment in NOD/SCID mice. 17 The role of CXCL12 in engraftment is not fully understood, as, in addition to facilitating BM homing, it has also been reported to stimulate the proliferation and survival of precursor B ALL cells. 18, 19 Therefore, it may have a role not only in precursor B ALL cells reaching a suitable microenvironment but also could potentially have a direct impact on precursor B ALL growth and survival.
A number of CXCR4 antagonists have been developed, including peptides based on CXCL12 itself, the Horseshoe crab self-defence protein polyphemusin II, and bicyclams such as AMD3100. 3 The polyphemusin II peptide analogues have been used to inhibit metastasis in animal models of breast cancer and melanoma 20, 21 while AMD3100 reduces the growth of neuronal and glial tumors in an animal model. 22 Our laboratory demonstrated that polyphemusin II peptide analogues T140, T134 and TC14012, and the bicyclam, AMD3100, are potent inhibitors of CXCL12-mediated chemotaxis and BM stromal-dependent proliferation of precursor B ALL cells. 19 However, the effect of disrupting CXCL12 binding to CXCR4 on the in vivo proliferation and survival of precursor B ALL cells is not known.
In this study, we examined the ability of CXCR4 antagonists to disrupt the interaction between precursor B ALL cells and their supportive niche in vivo. We found that blocking CXCL12/ CXCR4 interactions resulted in the rapid mobilization of leukemic cells into the PB, and resulted in a significant reduction in the expansion of precursor B ALL in NOD/SCID mice.
Materials and methods

Cells
Leukemic blasts were obtained from the BM of five patients (details are given in Table 1 ) with precursor B ALL, after informed consent and institutional ethics committee approval. Mononuclear cells were prepared and cryopreserved as described previously. 23 Cells were then expanded by passage through NOD/SCID mice and cells recovered from the spleens of these animals were used in experiments described here. The murine ALL cell line, MALL1, arose spontaneously in a NOD/ SCID mouse 125 days after irradiation. These cells require stromal support for in vitro growth but produce a transplantable B-cell progenitor leukemia in both NOD/SCID mice and irradiated Balb/c mice. 24 and was cultured in Roswell Park Memorial Institute containing 10% fetal calf serum.
Antibodies and reagents
The following monoclonal antibodies were purchased: anti-CXCR4-PE (12G5), anti-CD10-FITC (SS2/36), anti-CD19-APC (SJ25C1), anti-CD19-PE (4G7), anti-BrdU (B44), anti-murine CD45-FITC (30-F11), anti-murine B220-FITC (RA3-6B2), antimurine CD43-PE (S7), anti-murine Sca-1-FITC (E13.161.7), antimurine c-kit-PE (ack45) and the biotinylated mouse lineage panel and streptavidin-APC (BD Pharmingen, Sydney, Australia). Antimurine IgM-biotin was purchased from Southern Biotech (Birmingham, AL, USA). All antibodies were used as recommended by the manufacturer. 5-Bromodeoxyuridine (BrdU) was purchased from Amersham (Sydney, Australia) and Methocult for growing murine colonies from StemCell Technologies (Vancouver, British Columbia, Canada). CXCL12a was purchased from Mr Philip Owen (University of British Columbia, British Columbia, Canada). AMD3100 and AMD3465 were provided by AnorMED, 4-fluoro-benzoyl-TE14011-PLA and the control PLA were produced as described previously, 25 and the TC14012 peptide was synthesized by Mimotopes (Clayton, Victoria, Australia).
Chemotaxis assays
Chemotaxis assays were performed as described previously 19, 26 using Transwell Culture Inserts (Costar; Corning, NY, USA) with a pore size of 5 mm. A CXCL12 concentration of 200 ng/ml was used in the lower chamber in all experiments. Chemotaxis was measured after a 3 h incubation. The chemotactic index was then calculated by dividing the percentage of cells migrated in the presence of CXCL12 by the percentage of cells migrated in its absence. In some experiments, cells were treated with 1 mM AMD3100 or TC14012 for 2 h at 371C before plating in the assay. A viable cell gate was used to exclude dead cells from the analysis in both starting and migrated cell populations.
Proliferation and viability assays
Proliferation and viability assays were performed as described previously. 19 Briefly, ALL cells were plated on irradiated hTERT.BMS in AIM-V media alone or media containing 50 mM AMD3100 or TC14012 at a density of 5 Â 10 5 cells/ml. For assessment of proliferation 1 mCu of 3 H-thymidine (Pharmacia Amersham, San Jose, CA, USA) was added per well of sample after 4 days and incubated overnight at 371C. Cells were harvested onto glass fiber filters (Packard) followed by the addition of Microscint 40 for analysis on a TopCount plate reader. For assessment of cell survival, cells were harvested with trypsin/ethylene diaminetetraacetic acid, stained with annexin V fluorescein isothiocyanate and propidium iodide (BD Pharmingen, Sydney, Australia) according to the manufacturer's instructions and analyzed by flow cytometry.
Mobilization and engraftment assays
Mice received 2.5 Gy total body irradiation 24 h before administration of 5 Â 10 6 leukemic cells via tail vein injection. For mobilization assays, the leukemia was permitted to grow in the mice until leukemic cells could be detected in the PB by flow cytometry. Mice were then given 10 mg/kg of AMD3100, 40 mg/kg of TC14012 or phosphate-buffered saline (PBS) by subcutaneous (SC) injection and killed at indicated time points. PB was collected, cell counts performed and the percentage of leukemic cells determined by flow cytometry using antibodies to human CD19 and murine CD45. When using MALL1, leukemic cells were detected using staining for CD43 and B220. For engraftment studies, treatment was commenced 24 h after receiving leukemic cells, with mice receiving daily SC injections of 200 mg of AMD3100, AMD3465 or vehicle only, or two SC injections of 60 mg of 4-fluoro-benzoyl-TE14011-PLA or PLA only 2 weeks apart. Mice receiving continuous infusion of AMD3100 were implanted subcutaneously with ALZET osmotic pumps (ALZET, Cupertino, CA, USA) calibrated to release (12) 200 mg of AMD3100/day. Mice were killed on day 21, and BM, PB and spleens were analyzed for total cell numbers and the presence of leukemic cells by flow cytometry. Other organs were examined at autopsy and by histology as described previously. 27 Infiltration of the liver was quantitated by analyzing the cross-sectional area of liver sections that had been replaced by leukemic cells as assessed by histological examination.
Statistics
Comparisons between two groups were performed using Student's t-tests and between multiple groups using analysis of variance analysis. Pairwise comparisons between groups were adjusted for multiple comparisons using Bonferroni's method.
Results
Responses of precursor B ALL samples to CXCL12
We, and others, have reported that precursor B ALL cells express high levels of CXCR4 and that these cells undergo chemotaxis in response to CXCL12. 28, 29 CXCL12 is also reported to support ALL cell proliferation and survival. 18, 19 Cells from all the precursor B ALL cases examined in this study expressed high levels of CXCR4 on their cell surface (Table 1) . However, only three of the five cases responded to CXCL12 in chemotaxis assays (Table 1 ). AMD3100 and TC14012 completely blocked chemotaxis to CXCL12 in the three cases where chemotaxis was observed ( Table 1) . The in vitro stroma-supported proliferation of all the four cases tested was significantly inhibited by AMD3100 by between 13 and 89%, while survival was only inhibited in two of the four cases (Table 1) . Similar results were obtained using the peptide antagonist TC14012 (data not shown).
CXCR4 antagonists mobilize precursor B ALL cells into the PB
The CXCR4 antagonist, AMD3100, mobilizes hematopoietic progenitors from the BM. 7 Considering that precursor B ALL cells undergo chemotaxis to CXCL12 in a manner similar to normal hematopoietic progenitors, we explored the possibility that precursor B ALL cells may be similarly mobilized. NOD/ SCID mice engrafted with human precursor B ALL were treated with a single injection of AMD3100. This resulted in a rapid twofold increase (P ¼ 0.047) in the white cell count (WCC) peaking 1 h after drug administration (Figure 1a ). This is in keeping with the reported time of maximal mobilization of normal progenitors in mice. 7 The mobilized cells were predominantly leukemic with the percentage of leukemic cells increasing from 37.1710.1 to 64.377.7% (Po0.003) (Figure 1b ) and the leukemic cell count increasing from 0.3670.11 to 1.3570.78 Â 10 6 cells/ml (P ¼ 0.023) (Figure 1a) . In contrast, the number of normal white cells in the PB did not significantly increase (Figure 1a ). The total cellularity and the contribution of the leukemic population in the BM did not significantly change over the time of the experiment, with approximately 64% of BM cells being leukemic throughout. In the spleen, however, there was a small but significant decrease in both total cell numbers (from 135718 Â 10 6 to 103716 Â 10 6 , P ¼ 0.04) and the total ALL 6 , P ¼ 0.02) 3 h after administration of AMD3100. Similar results were obtained using the murine leukemic cells, MALL1, in Balb/c mice with a 1.8-fold increase in total WCC being observed 1 h post-injection (Figure 1d ). Leukemic cells were responsible for the majority of this increase with the percentage of leukemic cells in the PB increasing in each animal following AMD3100 treatment from a mean of 15.277.7 to 40.9714.5% (P ¼ 0.001) and absolute leukemic cell count increasing from 0.3370.12 to 2.1171.06 Â 10 6 cells/ml (P ¼ 0.001) (Figure 1e and f) and only a small statistically insignificant increase being observed in the normal population. There were small but statistically insignificant decreases in the leukemic cell number in the BM (from 2.070.7 Â 10 6 to 1.670.4 Â 10 6 cells/femur) and spleen (from 1.5470.60 Â 10 6 to 1.1070.28 Â 10 6 cells). To determine whether these effects were specific for AMD3100 or related more broadly to CXCR4 antagonists, we compared the effect of the peptide TC14012 with AMD3100. In this experiment, NOD/ SCID mice were engrafted with human leukemia. Mice were given PBS, AMD3100 or TC14012 and killed 1 h later. The CXCR4 antagonists inhibit the engraftment of precursor B ALL cells in NOD/SCID mice AMD3100 and a slow release form of the polyphemusin IIderived peptide 4-fluoro-benzoyl-TE14011 were able to reduce significantly the level of engraftment of human precursor B ALL cells in NOD/SCID mice when administered over a 20-day period. Daily administration of AMD3100 resulted in an overall 61% decrease in the absolute leukemic cell count in the PB when analyzed the day following the final injection of drug. The decrease was statistically significant in three of the five cases examined (Figure 2a and b) . There was also an overall 69% reduction in the leukemic cell counts in the spleens of the animals that achieved statistical significance in the same three cases (Figure 2c and d) .
Mobilization of ALL by AMD3100
The overall percentage of BM cells that were leukemic showed a small but significant reduction from 61735 to 52733% (P ¼ 0.017, n ¼ 5 xenografts, 24 control and 26 AMD3100-treated mice). However, there was no overall reduction in the total leukemic cell number in the BM of the animals, although there was a significant reduction in one case (1345) from 7.472.9 Â 10 6 to 4.170.9 Â 10 6 leukemic cells/ femur (P ¼ 0.04, n ¼ 5). In contrast to the impact of AMD3100 on ALL cells in vivo, there was no apparent effect of AMD3100 on normal hematopoiesis using the same treatment regimen on normal C57Bl6 mice (Table 2) .
In four of the above cases, we also examined the slow release compound 4-fluoro-benzoyl-TE14011-PLA. The peptide component of this compound is highly homologous to TC14012 but has greater resistance to digestion by liver enzymes and enhanced in vivo stability. 30 This compound produced a similar effect although it was less potent in the schedule used than the daily injections of AMD3100, with an overall reduction in leukemic cell number of 12% in the PB, being statistically significant in only one of the four cases (Figure 3a) , and 31% in Mobilization of ALL by AMD3100 J Juarez et al the spleen, being statistically significant in two of the four cases (Figure 3b ). No differences were detected between the leukemic cell content of the BM of 4-fluoro-benzoyl-TE14011-PLA-treated and PLA-treated mice.
Finally, we compared the efficacy of a continuous infusion of AMD3100 with that of daily SC injections. The total daily dose delivered was equivalent in both the protocols. We also examined equimolar doses of a newer compound, AMD3465, using daily SC injection. The percentage of ALL cells in the PB was significantly reduced by the three treatment regimens as compared to control animals but no significant differences were observed between the three treatment protocols (Figure 4a) . Similarly, the number of ALL cells present in the PB and the spleen was significantly reduced by each of the treatments with no significant differences being detected between treatment groups (B and C). In the BM, SC administration of AMD3100 resulted in a significant reduction in the number of ALL cells detected but, again, there were no significant differences among the three treatment protocols (Figure 4d ). This demonstrates that the intermittent administration is equally as effective as continuous administration and that the effect of AMD3100 is not related to nonspecific effects of the drug but is due to its ability to block CXCR4 since this effect can be reproduced by 4-fluoro-benzoyl-TE14011-PLA and AMD3465.
CXCR4 antagonists inhibit the dissemination of precursor B ALL cells in NOD/SCID mice
Examination of other tissues in the NOD/SCID mice revealed leukemic cell infiltration of the livers of mice receiving four (1999, 2032, 1345 and 1196) of the five cases. Although minor infiltration of the kidneys was also observed in mice receiving cells from the same four cases, only one case (1345) produced substantial renal involvement. No infiltration of the heart, lungs or brain was observed in any animals regardless of the patient sample used. Treatment with AMD3100 resulted in reduced leukemic cell infiltration in the livers of mice receiving cells from all cases and in the kidneys of animals receiving cells from case 1345 (Figure 5a-l) . By measuring the percentage of the cross-sectional area of the liver that had been infiltrated by leukemic cells, a significant reduction in leukemic cell infiltration of the liver was demonstrated in all the four cases (Figure 5m) . A similar reduction in ALL cell infiltration into the liver and kidneys of animals receiving 4-fluoro-benzoyl-TE14011-PLA was also observed, with significant reduction in tumor infiltration being observed in two of the four cases (from 51.3713.4% in control animals to 33.376.4% in treated animals (P ¼ 0.014) in case 1999 and from 36.1711.3 to 18.3713.9 (P ¼ 0.036) in case 2032). A closer examination of the nature of the infiltration in the liver revealed that AMD3100 significantly reduced the number of extramedullary sites in three of the four cases (Figure 5n ) but only significantly reduced the size of these in one case (Figure 5o ). This suggests that in most instances AMD3100 was inhibiting the ability of the ALL cells to seed the liver but not impeding their ability to grow once established. However, in the one case where the sites of leukemic involvement were reduced in size rather than number it appears that greatest impact of AMD3100 was on malignant cell growth in the liver.
Discussion
We have previously demonstrated that CXCL12 plays a significant role in the stromal-dependent proliferation of precursor B ALL cells, with marginal effects on survival, 19 while others have shown that CXCL12 improves survival.
18 CXCL12 has survival-enhancing effects on normal human and murine hematopoietic progenitors and although it enhances the proliferation of normal hematopoietic progenitors in stromafree in vitro culture, it inhibits the proliferation of these cells in stromal-dependent cultures and in vivo. 9, 31 We have demonstrated a predominant role for CXCL12 in the homing of ALL cells to the BM. 17 It also enhances precursor B ALL cell adhesion to fibronectin and VCAM-1 in BM stromal layers.
17,32 Therefore, we hypothesized that CXCL12 may be important for the retention of ALL cells within the supportive BM microenvironment, on which they are dependent for survival in vitro, and contribute to their in vivo proliferation within this microenvironment.
In this study, we demonstrated that disruption of the CXCL12/ CXCR4 interaction by a single SC injection of a CXCR4 antagonist results in the rapid mobilization of precursor B ALL cells into the PB. This is consistent with the apparent essential role for CXCR4 in the retention of HSC in the BM and the mobilizing effect of AMD3100 on normal HSC. 
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Interestingly, in these experiments we did not observe significant mobilization of normal BM cells, perhaps because the normal marrow was significantly depleted in the presence of the leukemic infiltrate decreasing the pool of normal cells available to be mobilized. Our data suggest that CXCR4 antagonists disrupt the interaction between the supportive BM microenvironment and precursor B ALL cells. Indeed, longer-term administration of CXCR4 antagonists reduced the number of leukemic cells in the PB and the spleens of NOD/SCID mice engrafted with human precursor B ALL, demonstrating that the disruption of CXCL12 signaling in precursor B ALL cells results in reduced expansion of the leukemic population in vivo. It is unclear whether this is due to reduced cell survival, reduced proliferation, or both, but our previously published in vitro studies suggest that inhibition of proliferation is likely to play a larger role than enhanced cell death. 19 We were unable to detect any difference in apoptosis or cell cycle between cells collected from treated and control animals. It is likely that the phagocytic removal of apoptotic cells in vivo has impeded our ability to detect these differences if present. Examination of BrdU incorporation failed to demonstrate any reduction in cell proliferation (data not shown); however, small changes in cell cycle may be sufficient to produce the changes in recovered cell numbers detected. In contrast to the effects of CXCR4 antagonists on leukemic populations in vivo, no effect on steady-state hematopoiesis was observed over the same time and using the same dosing schedule.
The inhibition of infiltration of extramedullary tissues including the liver and the kidney in antagonist-treated animals was a most striking and consistent finding. These data are consistent with that of Crazzolara et al., 34 who reported that high expression of CXCR4 is associated with the development of a more aggressive phenotype in patients with ALL, in which increased extramedullary organ infiltration is observed. The reduction in metastases may appear counterintuitive, considering that CXCR4 antagonists are mobilizing leukemic cells out of the marrow into the PB, providing them with increased opportunity to seed other tissues. However, the liver produces significant levels of CXCL12, so the inhibition of trafficking to this organ by CXCR4 antagonists is feasible. The reduction in the number of metastases in the livers of antagonist-treated animals in three of the four cases where liver involvement was evident, suggests that fewer cells may have reached the liver. However, the size of the lesions was also significantly smaller in antagonist-treated animals in case 1999 and a trend toward reduced size was evident in case 1345 suggesting that reduced growth of established foci also occurred. The inhibition of liver lesions in case 1345 is of particular interest since the cells from this patient did not undergo chemotaxis towards CXCL12 in vitro. It is possible that the apparent reduction in the number of foci could reflect a failure of the survival and/or proliferation of cells that have reached the liver. However, the absence of AMD3100-induced reduction of BrdU incorporation in liver infiltrating leukemic cells (data not shown) suggests that proliferation is not impaired. The liver is likely to provide a less supportive microenvironment than the BM, which could result in an increased dependence of precursor B ALL cells on CXCL12 in this setting. Inhibition of the growth of lung metastases by intrakine-mediated blockade of CXCR4 has previously been demonstrated by Zeelenberg et al. 35 in animals injected with the colon carcinoma line CT-26.
The role of CXCR4 and CXCL12 in hematological malignancies has been previously investigated in NOD/SCID models of non-Hodgkin's lymphoma 36 and acute myeloid leukemia. 37 Bertolini et al. 36 showed a reduction in the in vivo growth of non-Hodgkin's lymphoma and prolonged survival of tumorbearing mice as a result of 3 weekly injections of 100 mg of antihuman CXCR4 or polyclonal CXCL12 antibodies. Tavor et al. 37 showed a marked reduction in acute myeloid leukemia (AML) cell engraftment following weekly injections of only 10 mg/ml of CXCR4 antibody. However, the use of antibodies in these studies raises concerns relating to the specificity of the observed effects. In the same study, Tavor et al. 37 also demonstrated dramatic 84% inhibition of the engraftment of normal HSC when treatment was commenced within 2 days but that no effect was observed when treatment was delayed until engraftment was established. This was interpreted as CXCR4 being important for the homing but not subsequent events involved in BM engraftment. However, recent studies by a number of groups now suggest that CXCR4 plays little, if any, role in the homing of normal HSC. 33, 38, 39 It is possible that the CXCR4 antibody plays a significant but nonspecific role in the elimination of both normal and malignant cells from the circulation. Despite this, the ability of CXCR4 antibodies to inhibit the growth of established engrafted AML cells suggests that CXCR4 is probably involved in the progression of AML in vivo.
The modest effects of CXCR4 antagonists when used as single agents makes these compounds unlikely candidates for singleagent therapy for leukemias. However, antagonists of CXCR4 may improve the efficacy of chemotherapeutic agents and radiotherapy for two reasons. First, stromal interactions have been reported to protect leukemic cells from the effects of chemotherapeutic agents. 40 Second, chemotherapy and radiotherapy can enhance the production of CXCL12 within the BM resulting in enhanced protection from cell death. 41 Together, our data demonstrate that CXCR4 antagonists significantly inhibit the growth and dissemination of ALL in vivo while having no effect on normal hematopoiesis. We therefore propose that CXCR4 antagonists have potential therapeutic application for the treatment of ALL.
